Antibody-drug conjugates (ADC) are booming in the biotech industry this year with mounting investment and M&A deals. Here are five ADC players that have caught the eye of investors in the last 12 months.
– Star’s innovation engine has driven rapid advancement of internally discovered first‑in‑class antibody therapeutics into the clinic, attracting leading life sciences investors– Financing supports Vega Therapeutics, a clinical stage company focused on underserved blood disorders, as well as the advancement of addit.
Startup Star Therapeutics will use the Series B funding to support clinical development of a drug candidate for von Willebrand disease, a bleeding disorder. The capital will also support the formation of new biotech subsidiaries developing antibodies with therapeutic applications in hematology and immunology.